CAPR Falls 5.6% After Securities Class Action Filed
Capricor Therapeutics (NASDAQ: CAPR) slid 5.6% on Aug 18, 2026 after investors were alerted to a securities class action tied to claims about the company’s messaging around FDA approval for its lead drug candidate.
What Capricor Therapeutics announced
Investors were informed that a securities class action lawsuit has been filed on behalf of people and entities that bought or acquired Capricor securities during a stated class period running from December 17, 2025 to July 26, 2026.
According to the notice, the lawsuit alleges Capricor misled investors about the path to FDA approval for its lead product candidate, Deramiocel. Deramiocel is described as an investigational cell therapy aimed at addressing cardiac and skeletal muscle complications associated with Duchenne muscular dystrophy (DMD).
The summary also points to the company’s prior regulatory history referenced in the complaint, including a Biologics License Application (BLA) submission and an FDA Complete Response Letter that said the BLA did not meet the statutory requirement for substantial evidence of effectiveness and requested additional clinical data. The notice includes a deadline of September 28, 2026 for investors who want to seek appointment as lead plaintiff.
What it means for Capricor Therapeutics
A class action like this can raise the stakes around how investors interpret past statements, especially when the core allegation centers on the regulatory “roadmap” for a lead program.
For a biotech company focused on rare diseases, the lead asset often drives the narrative. If the dispute becomes a recurring headline, it could keep attention on regulatory uncertainty and the need for additional clinical data, rather than on forward progress.
The case also underscores how sensitive biotech valuations can be to FDA process details, particularly around whether the evidence package is viewed as sufficient for approval.
How the stock reacted
CAPR started the session with a brief pop, but the move reversed and accelerated lower into the close.
| Window | Move |
|---|---|
| 5 min | +1.1% |
| 10 min | +0.6% |
| 30 min | -3.2% |
| 1 hour | -4.9% |
| end of day | -5.6% |
On a market-adjusted basis, the stock underperformed the SPY by 5.5% on the day.